Kylla has taken an equity stake in Elmed Agrobiotics to help build a science-led probiotics platform in Europe, with a clear emphasis on research, validation and next-generation product development. The partnership brings together industrial manufacturing and formulation capabilities with European structuring and close links to Wageningen University & Research (WUR). Together, the parties aim to create a robust innovation engine across animal health, aquaculture and sustainable agriculture—grounded in scientific evidence and designed to support long-term, differentiated product pipelines.
Kylla Capital Partners has taken a strategic equity stake in Elmed Agrobiotics BV, the European entity linked to ELMED Life Sciences Pvt Ltd. The transaction formalises a long-term partnership focused on strengthening the group’s European R&D footprint, accelerating applied research trajectories, and translating microbiome science into validated, scalable probiotic solutions.
The investment reflects Kylla’s conviction that microbial technologies will play an increasingly central role in food security, antibiotic reduction and regenerative farming—particularly in Europe, where scientific standards, regulatory expectations and proof requirements are shaping the next wave of adoption.
Building a research-driven platform for the next product generation
ELMED Life Sciences has developed integrated manufacturing and formulation capabilities in probiotics, spanning multiple dosage forms and application areas.
Through Elmed Agrobiotics, the group aims to complement this industrial backbone with a European innovation platform that prioritises:
- evidence generation and validation,
- strain and formulation optimisation, and
- product development tailored to European farming and aquaculture systems.
Rather than positioning the European entity primarily as a commercial rollout vehicle, the near-term focus is on establishing a stronger scientific base—ensuring that future market activity is supported by credible data packages, field validation, and clear performance claims aligned with European standards.
Strategic rationale: scientific credibility, validation capacity, long-term differentiation
Europe is a demanding environment for probiotics, where long-term success increasingly depends on scientific substantiation and consistent performance across real-world conditions. Kylla identified three pillars underpinning the investment case:
- A manufacturing backbone capable of producing stable, repeatable formulations at scale;
- A multi-segment development platform aligned with a One Health approach across animals, aquaculture and agriculture;
- A European entity designed for governance, compliance and scientific positioning, enabling rigorous validation and credible stakeholder engagement.
This combination is intended to create a durable foundation for a differentiated product portfolio—rather than a short-term market-push strategy.
The role of science and Wageningen University & Research
Anton van der Graaf, Managing Partner at Kylla, comments: “We see probiotics and microbial technologies as a structural theme across animal health, sustainable agriculture and food security. Our investment in Elmed Agrobiotics is primarily about strengthening a science-led platform in Europe—building evidence, improving formulations, and creating a foundation for future product development. In that context, the connection with Wageningen University & Research is strategically important. Wageningen is globally recognised for its expertise in agri-food, microbiology and sustainable farming systems. Linking industrial capability with leading academic insight enhances credibility, accelerates learning cycles, and supports the development of products that can meet Europe’s high validation and compliance expectations.”
The connection with Wageningen University & Research underscores the intent to anchor the platform in scientific rigour. Access to a leading European agri-food research ecosystem strengthens Elmed Agrobiotics’ ability to design, test and validate solutions under relevant European conditions—supporting product claims, performance consistency and long-term innovation.
Kylla’s active shareholder role
Kylla’s involvement extends beyond capital. As an active shareholder, Kylla will support the structuring of the European entity, governance and compliance, and the set-up of partnerships that enable research collaboration, field validation and pathway planning for future products.
As scientific progress and validation milestones are achieved, the platform will evaluate options for subsequent growth funding—aligned with measurable proof points and a maturing product pipeline.
Next phase
Over the coming 12 to 24 months, priorities include:
* establishing a structured R&D and validation agenda in Europe,
* initiating applied research collaborations and field validation pathways,
* generating data packages to support future product claims and regulatory positioning, and
* defining a product development roadmap across animal health, aquaculture and sustainable agriculture.
Any commercial expansion will follow as outcomes are validated and the portfolio is strengthened—ensuring that future growth is built on scientific credibility and robust product performance.
With this investment, Kylla reinforces its commitment to backing scalable life sciences platforms—particularly where industrial execution is paired with scientific excellence and long-term innovation capacity.
Managing Partner
Kylla Corporate Transactions
